Inventor · disambiguated record
Joaquim Trias
Also filed as: TRIAS JOAQUIM
5 granted patents·13 pending applications·140 citations·filing 1993–2024
80Inventor score
Files withARIXA PHARMACEUTICALS INC4HISLOP COLIN4MICROCIDE PHARMACEUTICALS INC2TRIAS JOAQUIM2ANTHERA PHARMACEUTICALS INC1
Top patents by PatentIndex Score
18 records- 0179US5989832AMethod for screening for non-tetracycline efflux pump inhibitorsMICROCIDE PHARMACEUTICALS INC·Filed 1995·Granted Nov 23, 1999·74 cites·110 claims
- 0272US2024245705A1Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infectionsARIXA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0371US5883074APotentiators of antibacterial agentsMICROCIDE PHARMACEUTICALS INC·Filed 1995·Granted Mar 16, 1999·47 cites·55 claims
- 0466US8048880B2Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapiesANTHERA PHARMACEUTICALS INC·Filed 2008·Granted Nov 1, 2011·2 cites·30 claims
- 0566US2023210863A1Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infectionsARIXA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0659US2021186983A1Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infectionsARIXA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0752US2021060033A1Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infectionsARIXA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0849US2003109583A1Administration of negamycin or deoxynegamycin for the treatment of bacterial infectionsFiled 2002·Application pending·0 cites
- 0946US5830457ARecombinant beta-lactamase, usable as carrier molecule in immunogenic compositionsPASTEUR INSTITUT·Filed 1993·Granted Nov 3, 1998·17 cites·40 claims
- 1039US2010160361A1Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapiesHISLOP COLIN·Filed 2009·Application pending·0 cites
- 1136US2003125389A1Beta-amino acid derivatives useful for the treatment of bacterial infectionsFiled 2002·Application pending·0 cites
- 1235US2009062369A1Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levelsTRIAS JOAQUIM·Filed 2007·Application pending·0 cites
- 1335US2008299585A1METHODS FOR DETECTION AND MEASUREMENT OF SECRETORY PHOSPHOLIPASE A2 LEVELS (sPLA2) IN BIOLOGICAL FLUIDSTRUEX PAUL·Filed 2007·Application pending·0 cites
- 1431US11103589B2Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereofAPG THERAPEUTICS INC·Filed 2017·Granted Aug 31, 2021·0 cites·11 claims
- 1531US2011269786A1Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapiesHISLOP COLIN·Filed 2011·Application pending·0 cites
- 1630US2011301202A1Spla2 inhibitor conjugate compounds and methods of useHISLOP COLIN·Filed 2011·Application pending·0 cites
- 1729US2011207710A1Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapiesTRIAS JOAQUIM·Filed 2011·Application pending·0 cites
- 1819US2010204249A1Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemiaHISLOP COLIN·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →